Views from Our CEO: How to Future-proof Biomanufacturing

Lars Petersen, president and CEO, FUJIFILM Biotechnologies:

“Every day customers reach out to me asking how to futureproof manufacturing. My answer to them is simple: dual sourcing, meaning manufacturing in two different countries.

At FUJIFILM Biotechnologies, we offer biomanufacturing capacity readily available across the globe, helping our customers manage and mitigate the potential impacts of geopolitical developments.

We are able to offer dual sourcing through our network due to our proprietary kojoX platform. KojoX is a first-of-its-kind modular approach with standardized equipment, processes, and procedures across our sites, which ensures supply chain resilience.

Our team is always anticipating the needs of our customers. Here’s why our partners trust us:

First and foremost, our exceptional people, from our construction partners that are rapidly building our facilities at speed, to our scientists and engineers that are making our partners’ medicines, and our administrative staff that ties it all together
Proven historical track record of $8 billion+ investment and rapid expansion in the US and Europe
A DNA rooted in Life Sciences
160,000 L large-scale capacity in North Carolina this year, which we will double in 2028 including Fill & Finish
240,000 L large-scale capacity in Denmark with 400,000 L by 2026 including Fill & Finish
Unique kojoX approach driving operational excellence, and unprecedented integration across the network to maximize efficiency in delivering medicines.
In addition, we will open 2K, 5K facility in Billingham, UK in 2026, and in Toyama, Japan in 2027 also based on our dual sourcing kojoX integrated manufacturing network concept and an option to replicate same design into our Texas facility where the shell is already established

We focus and perfect the biomanufacturing strategy so our partners can concentrate on developing life-impacting treatments for patients worldwide.

I’m proud to be their trusted manufacturing partner in ensuring critical medicines reach patients, regardless of country or circumstance.”